tiprankstipranks
H.C. Wainwright Reaffirms Their Buy Rating on Tempest Therapeutics (TPST)
Blurbs

H.C. Wainwright Reaffirms Their Buy Rating on Tempest Therapeutics (TPST)

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Tempest Therapeutics (TPSTResearch Report), with a price target of $35.00. The company’s shares closed last Friday at $1.45.

Pantginis covers the Healthcare sector, focusing on stocks such as Tempest Therapeutics, Onconova Therapeutics, and Cytokinetics. According to TipRanks, Pantginis has an average return of 1.7% and a 40.54% success rate on recommended stocks.

Tempest Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $18.33.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $4.21 and a one-year low of $1.06. Currently, Tempest Therapeutics has an average volume of 253.8K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Millendo Therapeutics, Inc. is a biopharmaceutical company. The company is engaged in the development of novel treatments for endocrine diseases. Its products include livoletide and nevanimibe. The company was founded in April, 2011 and is headquartered in Ann Arbor, MI.

Read More on TPST:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles